Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion - Bonner, Caroline; Kerr-Conte, Julie; Gmyr, Valéry; Queniat, Gurvan; Moerman, Ericka; Thévenet, Julien; Beaucamps, Cédric; Delalleau, Nathalie; Popescu, Iuliana; Malaisse, Willy J; Sener, Abdullah; Deprez, Benoit; et al. (Nature medicine, 2015)
Keywords: 14; 14/19; 38/1; 38/109; 38/39; 38/89; 692/699/2743/137/773; 82; Administration, Oral; Adult; Animals; Benzhydryl Compounds - chemistry; Biomedicine; Blood Glucose - chemistry; Cancer Research; Carrier proteins; Cell Separation; Dapagliflozin; Dosage and administration; Drug therapy; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation; Gene Silencing; Glucagon; Glucagon - blood; Glucagon - metabolism; Glucagon-Secreting Cells - metabolism; Gluconeogenesis; Glucose; Glucosides - chemistry; Health aspects; Hepatocyte Nuclear Factor 4 - metabolism; Humans; Infectious Diseases; Insulin Resistance; letter; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Molecular Medicine; Neurosciences; Pancreas; RNA, Small Interfering - metabolism; Sodium-Glucose Transporter 1 - metabolism; Sodium-Glucose Transporter 2 - metabolism; Type 2 diabetes